Literature DB >> 14695774

HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage.

Ying Chen1, Johnny Sze, Ming-Liang He.   

Abstract

AIM: To evaluate the covalently closed circle DNA (cccDNA) level of hepatitis B virus (HBV) in patients' liver and sera.
METHODS: HBV DNA was isolated from patients' liver biopsies and sera. A sensitive real-time PCR method, which is capable of differentiation of HBV viral genomic DNA and cccDNA, was used to quantify the total HBV cccDNA. The total HBV viral DNA was quantitated by real-time PCR using a HBV diagnostic kit (PG Biotech, LTD, Shenzhen, China) described previously.
RESULTS: For the first time, we measured the level of HBV DNA and cccDNA isolated from ten HBV patients' liver biopsies and sera. In the liver biopsies, cccDNA was detected from all the biopsy samples. The copy number of cccDNA ranged from from 0.03 to 173.1 per cell, the copy number of total HBV DNA ranged from 0.08 to 3 717 per cell. The ratio of total HBV DNA to cccDNA ranged from 1 to 3 406. In the sera, cccDNA was only detected from six samples whereas HBV viral DNA was detected from all ten samples. The ratio of cccDNA to total HBV DNA ranged from 0 to 1.77%. To further investigate the reason why cccDNA could only be detected in some patients' sera, we performed longitudinal studies. The cccDNA was detected from the patients' sera with HBV reactivation but not from the patients' sera without HBV reactivation. The level of cccDNA in the sera was correlated with ALT and viral load in the HBV reactivation patients.
CONCLUSION: HBV cccDNA is actively transcribed and replicated in some patients' hepatocytes, which is reflected by a high ratio of HBV total DNA vs cccDNA. Detection of cccDNA in the liver biopsy will provide an end-point for the anti-HBV therapy. The occurrence of cccDNA in the sera is an early signal of liver damage, which may be another important clinical parameter.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695774      PMCID: PMC4717084          DOI: 10.3748/wjg.v10.i1.82

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  A novel stop codon mutation in HBsAg gene identified in a hepatitis B virus strain associated with cryptogenic cirrhosis.

Authors:  Xu Yang; Xiao-Peng Tang; Jian-Hua Lei; Hong-Yu Luo; Yong-Hong Zhang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

3.  Inhibition of hepatitis B virus replication by stably expressed shRNA.

Authors:  Ying Chen; Dan Du; Jun Wu; Chun-Pong Chan; Yuequi Tan; Hsiang-fu Kung; Ming-Liang He
Journal:  Biochem Biophys Res Commun       Date:  2003-11-14       Impact factor: 3.575

Review 4.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

5.  Dynamics of hepatitis B virus infection in vivo.

Authors:  S Zeuzem; R A de Man; P Honkoop; W K Roth; S W Schalm; J M Schmidt
Journal:  J Hepatol       Date:  1997-09       Impact factor: 25.083

6.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.

Authors:  M Tsiang; J F Rooney; J J Toole; C S Gibbs
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

7.  Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

Authors:  S R Lewin; R M Ribeiro; T Walters; G K Lau; S Bowden; S Locarnini; A S Perelson
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

8.  Hepatitis B virus infection of transplanted human hepatocytes causes a biochemical and histological hepatitis in immunocopetentent rats.

Authors:  Catherine H Wu; Edwin C Ouyang; Cherie Walton; Kittichai Promrat; Faripour Forouhar; George Y Wu
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

9.  Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.

Authors:  Richard K Gaillard; Jennifer Barnard; Vincent Lopez; Paula Hodges; Eric Bourne; Lance Johnson; Marchelle I Allen; Patrick Condreay; Wayne H Miller; Lynn D Condreay
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

10.  Abnormal immunity and gene mutation in patients with severe hepatitis-B.

Authors:  Jing-Yan Wang; Pei Liu
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

View more
  17 in total

1.  Relationship between genotypes and clinical manifestation, pathology, and cccDNA in Chinese children with hepatitis B virus-associated glomerulonephritis.

Authors:  Yong-Hong Sun; Xiao-Yan Lei; Yi-Pa Sai; Jun-Hui Chen; Yuan-Chun Sun; Xia Gao
Journal:  World J Pediatr       Date:  2016-04-08       Impact factor: 2.764

Review 2.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

3.  Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.

Authors:  Edward M Kennedy; Leda C Bassit; Henrik Mueller; Anand V R Kornepati; Hal P Bogerd; Ting Nie; Payel Chatterjee; Hassan Javanbakht; Raymond F Schinazi; Bryan R Cullen
Journal:  Virology       Date:  2014-12-29       Impact factor: 3.616

4.  DNA Repair Factor Poly(ADP-Ribose) Polymerase 1 Is a Proviral Factor in Hepatitis B Virus Covalently Closed Circular DNA Formation.

Authors:  Yingshan Chen; Yongxuan Yao; Kaitao Zhao; Canyu Liu; Yifei Yuan; Hao Sun; Dan Huang; Yi Zheng; Yuan Zhou; Jizheng Chen; Yun Wang; Chunchen Wu; Bixiang Zhang; Yujuan Guan; Feng Li; Rongjuan Pei; Xinwen Chen
Journal:  J Virol       Date:  2022-06-07       Impact factor: 6.549

5.  Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice.

Authors:  Franck Amblard; Sebastien Boucle; Leda Bassit; Bryan Cox; Ozkan Sari; Sijia Tao; Zhe Chen; Tugba Ozturk; Kiran Verma; Olivia Russell; Virgile Rat; Hugues de Rocquigny; Oriane Fiquet; Maud Boussand; James Di Santo; Helene Strick-Marchand; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

6.  Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients.

Authors:  Bhupesh Singla; Anuradha Chakraborti; Bal Krishan Sharma; Shweta Kapil; Yogesh K Chawla; Sunil K Arora; Ashim Das; Radha K Dhiman; Ajay Duseja
Journal:  Mol Biol Rep       Date:  2014-04-06       Impact factor: 2.316

7.  The Human Bocavirus Is Associated with Some Lung and Colorectal Cancers and Persists in Solid Tumors.

Authors:  Verena Schildgen; Monika Malecki; Ramona-Liza Tillmann; Michael Brockmann; Oliver Schildgen
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

8.  Development of magnetic capture hybridization and quantitative polymerase chain reaction for hepatitis B virus covalently closed circular DNA.

Authors:  Yongcan Guo; Shangchun Sheng; Bin Nie; Zhiguang Tu
Journal:  Hepat Mon       Date:  2015-01-05       Impact factor: 0.660

9.  Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs.

Authors:  Jingwei Ma; Chunmei Huang; Xinxin Yao; Chuan Shi; Lifang Sun; Lu Yuan; Ping Lei; Huifen Zhu; Hongbo Liu; Xiongwen Wu; Qin Ning; Chun Zhou; Guanxin Shen
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

10.  CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

Authors:  Madina Karimova; Niklas Beschorner; Werner Dammermann; Jan Chemnitz; Daniela Indenbirken; Jan-Hendrik Bockmann; Adam Grundhoff; Stefan Lüth; Frank Buchholz; Julian Schulze zur Wiesch; Joachim Hauber
Journal:  Sci Rep       Date:  2015-09-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.